๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma

โœ Scribed by Kadri Altundag; Ozden Altundag; Paolo Morandi; Mehmet Gunduz

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
59 KB
Volume
101
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

High-dose calcitriol, zoledronate, and d
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma
โœ Michael J. Morris; Oren Smaletz; David Solit; W. Kevin Kelly; Susan Slovin; Carl ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 97 KB

## Abstract ## BACKGROUND Preclinical and clinical data have suggested that highโ€dose calcitriol (1,25โ€dihydroxycholecalciferol) has activity against prostate carcinoma. Pulseโ€dosed calcitriol and dexamethasone may maximize tolerability and efficacy. The authors examined the toxicity of pulseโ€dose

High-dose weekly oral calcitriol in pati
High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma
โœ Tomasz M. Beer; Dianne Lemmon; Bruce A. Lowe; W. David Henner ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 97 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND In preclinical systems, calcitriol, the natural vitamin D receptor (VDR) ligand, has been found to demonstrate antiproliferative effects, although concentrations > 1 nM are required. Unlike daily dosing, weekly administration of oral calcitriol can safely achieve such blo

Phase II trial of cyclophosphamide, vinc
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma
โœ Danai D. Daliani; Vasily Assikis; Shi-Ming Tu; Christos N. Papandreou; Lance C. ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 105 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND In this Phase II study, the authors assessed the toxicity and antiโ€tumor activity of a combination of oral cyclophosphamide, oral lowโ€dose dexamethasone, and intravenous vincristine (CVD) in patients with metastatic androgenโ€independent prostate carcinoma (AIโ€PCa). ## ME

Novel strategies and therapeutics for th
Novel strategies and therapeutics for the treatment of prostate carcinoma
โœ Michael J. Morris; Howard I. Scher ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 222 KB ๐Ÿ‘ 2 views

An increased understanding of the biology of prostate carcinoma has led to the clinical evaluation of mechanism-based and targeted therapies. Modulating the immune system has been pursued through the use of both active and passive immunity as well as the ex vivo genetic manipulation of effector cell